Chemoprevention of colorectal cancer

American Journal of Gastroenterology

Volumn 97, Issue 1, 2002, Pages 13-21

  Gwyn, Karin ^a   Sinicrope, Frank A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CALCIUM CARBONATE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PRAVASTATIN; SELENIUM; SIMVASTATIN; SULINDAC; URSODEOXYCHOLIC ACID;

ADENOMA; ADENOMATOUS POLYP; AGED; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; DIETARY FIBER; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOD AND DRUG ADMINISTRATION; GENETIC MANIPULATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; RAT; REVIEW; THROMBOCYTOPENIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASCORBIC ACID; BETA CAROTENE; CALCIUM COMPOUNDS; COLORECTAL NEOPLASMS; DIETARY FIBER; DIETARY SUPPLEMENTS; EFLORNITHINE; ENZYME INHIBITORS; FEMALE; FOLIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; URSODEOXYCHOLIC ACID; VITAMIN E;

EID: 0036142033     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)03997-1     Document Type: Review

References (91)

1. Cancer statistics, 2001
2. Genetic alterations during colorectal-tumor development
3. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup
4. Colorectal cancer: Molecules and populations
5. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer
6. Reduced risk of large-bowel adenomas among aspirin users
7. Aspirin use and reduced risk of fatal colon cancer
8. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
9. Aspirin and the risk of colorectal cancer in women
10. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer
11. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physician's Health Study
12. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis
13. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
14. A protective effect of sulindac against chemically-induced primary colonic tumours in mice
15. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat
16. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds
17. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment
18. Human cyclooxygenase-2 cDNA
19. Selective expression of mitogen-inducible cycooxygenase in macrophages stimulated with lipopolysaccharide
20. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
21. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2)
22. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
23. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo
24. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
25. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group
26. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
27. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
28. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
29. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis
30. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IKBa phosphorylation and degradation
31. Inhibition of NF-KB by sodium salicylate and aspirin
32. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
33. Sulindac for polyposis of the colon
34. Treatment of colonic and rectal ademomas with sulindac in familial adenomatous polyposis
35. Rectal cancer after prolonged sulindac chemoprevention. A case report
36. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy
37. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
38. 2 levels in rat colon
39. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
40. Effect of sulindac on sporadic colonic polyps
41. NSAID effect on sporadic colon polyps
42. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential chemopreventative agents
43. Aberrant crypt foci of the colon as precursors of adenoma and cancer
44. An ornithine decarboxylase-deficient mutant of Chinese hamster ovary cells
45. The ornithine decarboxylase gene is a transcriptional target of c-Myc
46. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene
47. α-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin
48. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylornithine with piroxicam or fish oil
49. Effect of D,L-2-difluoromethylornithine and endocrine manipulation on the induction of mammary carcinogenesis by 1-methyl-l-nitrosourea
50. Inhibition of carcinogenesis by α-difluoromethylornithine in heterotopically transplanted rat urinary bladders
51. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa
52. Effect of α-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention
53. Randomized phase I chemoprevention dose-seeking study of alpha-difluromethylornithine
54. Phase II trials of α-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer
55. A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma
56. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet
57. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
58. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in Scandinavian simvastatin survival study
59. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin, and simvastatin, in ICR mice
60. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats
61. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventative effects of sulindac
62. Acute and chronic effect of dietary cholic acid on colonic epithelial cell proliferation
63. Effect of cholic acid feeding on N-methyl-N-nitrosourea-induced colon tumors and cell kinetics in rats
64. Effect of dietary deoxycholic acid and cholesterol on fecal steroid concentration and its impact on colonic crypt cell proliferation in azoxymethane-treated rats
65. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer
66. Differing effect of chenodeoxycholic acid and ursodeoxycholic acid on bile acids in rat colonic wall and contents
67. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid
68. Inhibitory effects of ursodeoxycholic acid on N-methyl-nitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats
69. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis
70. Calcium supplements for the prevention of colorectal adenomas
71. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: A randomised intervention trial
72. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study
73. Folate, methionine, and alcohol intake, and the risk of colorectal adenoma
74. DNA methylation as an intermediate biomarker in colorectal cancer: Modulation by folic acid supplementation
75. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease
76. Effects of supplemental α-tocopherol and β-carotene on colorectal cancer: Results from a controlled trial (Finland)
77. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis
78. A randomized trial of vitamins C and E in the prevention of recurrence of colorectal polyps
79. A clinical trial of antioxidant vitamins to prevent colorectal adenoma
80. Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas
81. The epidemiology of selenium and human cancer
82. Dietary selenium reduces the formation of aberrant crypts in rats administered 3,2′-dimethyl-4-aminobiphenyl
83. Lack of chemopreventive efficacy of DL-selenomethionine in colon carcinogenesis
84. Chemoprevention of colon cancer by organoselenium compounds and impact of high-or low-fat diets
85. min mouse model by 1,4-phenylene bis(methylene)selenocyanate
86. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial
87. Dietary fiber and the risk of colorectal cancer and adenoma in women
88. Lack of effect of a low-fat, high fiber diet on the recurrence of colorectal adenomas
89. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas
90. Randomized trial of intake of fat, fiber, and beta-carotene to prevent colorectal adenomas
91. Causes of death in familial adenomatous polyposis